FDA Scrutiny of Wellness Peptides Draws New Attention

KFF Health News journalists fanned out across national and local media to explain several stories shaping public health, according to KFF Health News. The thread with the clearest industry stakes: mounting Food and Drug Administration scrutiny of peptides, the compounds now widely marketed online for weight loss, muscle growth, and anti-aging.

Peptides have exploded as a consumer wellness category, often sold through compounding pharmacies, telehealth clinics, and gray-market suppliers with limited proof of safety or efficacy. FDA attention signals that regulators are watching how these products are made, marketed, and prescribed, a warning for the telehealth and longevity businesses building around them.

The same roundup touched a congressional hearing involving Anthony Fauci, disputes over Environmental Protection Agency grants, and growing caffeine consumption among children. Together the segments map where regulatory and public-health energy is heading: consumer-facing wellness products, federal accountability, and pediatric health risks that companies and clinicians will increasingly need to navigate.